Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This defect is at least partially linked to a decreased or absent expression of some activating NK cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia vera). The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors.
| Condition | Intervention |
|---|---|
|
Polycythemia Vera |
Biological: blood sample |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
- To describe immunologic anomalies in polycythemia vera [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 27 |
| Study Start Date: | July 2009 |
| Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
-
Biological: blood sample
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
VAQUEZ'S DISEASE
Inclusion Criteria:
- Polycythemia vera
- Treatment by therapeutic bleedings
- No cytotoxic treatment during the previous six months
Exclusion Criteria:
- No Polycythemia vera
- No treatment by therapeutic bleedings
- Cytotoxic treatment during the previous six months
Contacts and Locations| Contact: Regis Costello | regis.costello@ap-hm.fr |
| France | |
| Assistance Publique - Hopitaux de Marseille | Recruiting |
| Marseille, France | |
| Contact: Regis Costello regis.costello@ap-hm.fr | |
| Principal Investigator: Regis Costello | |
| Principal Investigator: | Regis Costello | Assistance Publique Hopitaux De Marseille |
More Information
No publications provided
| Responsible Party: | Assistance Publique Hopitaux De Marseille, Direction de la recherche |
| ClinicalTrials.gov Identifier: | NCT01284712 History of Changes |
| Other Study ID Numbers: | 2009/16, 2009-A00395-52 |
| Study First Received: | August 3, 2009 |
| Last Updated: | January 26, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Assistance Publique Hopitaux De Marseille:
|
treatment by bleedings |
Additional relevant MeSH terms:
|
Polycythemia Polycythemia Vera Hematologic Diseases Myeloproliferative Disorders Bone Marrow Diseases |
ClinicalTrials.gov processed this record on May 21, 2013